Cyclerion Therapeutics (CYCN) Return on Equity (2019 - 2025)
Historic Return on Equity for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to 0.46%.
- Cyclerion Therapeutics' Return on Equity fell 1000.0% to 0.46% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.46%, marking a year-over-year decrease of 1000.0%. This contributed to the annual value of 0.67% for FY2023, which is 15500.0% up from last year.
- Per Cyclerion Therapeutics' latest filing, its Return on Equity stood at 0.46% for Q3 2025, which was down 1000.0% from 0.36% recorded in Q2 2025.
- Cyclerion Therapeutics' Return on Equity's 5-year high stood at 1.12% during Q2 2024, with a 5-year trough of 4.47% in Q2 2023.
- Its 5-year average for Return on Equity is 1.1%, with a median of 0.99% in 2021.
- Per our database at Business Quant, Cyclerion Therapeutics' Return on Equity plummeted by -28100bps in 2023 and then soared by 55900bps in 2024.
- Quarter analysis of 5 years shows Cyclerion Therapeutics' Return on Equity stood at 1.06% in 2021, then tumbled by -149bps to 2.62% in 2022, then surged by 107bps to 0.18% in 2023, then plummeted by -294bps to 0.35% in 2024, then decreased by -30bps to 0.46% in 2025.
- Its Return on Equity stands at 0.46% for Q3 2025, versus 0.36% for Q2 2025 and 0.32% for Q1 2025.